Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procter & Gamble Co.

www.pg.com

Latest From Procter & Gamble Co.

Aleve Challenge, New Study Catch Up To Advil 'Works Longer' Claim In NAD Review

Although 1993 studies to make Aleve available OTC didn't support claiming the naproxen oral analgesic lasted longer than ibuprofen-containing Advil, 2018 study Bayer submitted for National Advertising Division review shows Advil's efficacy doesn't exceed Aleve's. Report also says while Pfizer criticized inpatient methodology of Bayer's study, inpatient is industry standard method for pain medication trials.

OTC Drugs Ad Complaints

P&G Sitting Pretty Three Years After Beauty Brand Purge

Procter & Gamble has entered a new growth phase that leadership says validates its portfolio rationalization choices. The firm’s Beauty business, lighter by more than 40 brands that went to Coty in October 2016, achieved 4% organic growth in fiscal 2019. CEO David Taylor offered perspective on this "disrupted" P&G at the Barclays Global Consumer Staples Conference.

Beauty Commercial

Perrigo Feeds OTC Brand Play With Prevacid As GSK Thins Consumer Lineup

Already providing generic equivalents, Perrigo buys national brand from GSK as it acts on commitment to move into brand product sales. Plans to expand OTC Prevacid line, likely with an orally disintegrating tablet, and to grow entire US OTC gastrointestinal category.

OTC Drugs Commercial

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Sanofi's push to concentrate its Consumer Healthcare portfolio on priority categories sees it offload two OTC brands in Germany and Austria. Meanwhile, new Sanofi CEO Paul Hudson has spoken about his intention to review the firm's plans in the OTC market. 
Deals Germany
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register